The table below shows Viridian Therapeutics, Inc.DE's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$119.65M
-$92.65M
-$45.22M
-$61.97M
-$21.04M
-$11.54M
Capital expenditure
$23.00K
$86.00K
$0.00
$115.00K
$179.00K
$15.00K
Investing cash flow
$77.26M
$100.06M
-$143.04M
-$13.29M
$8.86M
$10.87M
Dividends paid
-
-
-
-
VRDN operating cash flow (10-K history)
Viridian Therapeutics, Inc.DE reported operating cash flow of -$276.39M for fiscal year 2025. That is down 19.0% from -$232.32M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$14.76M (FY 2016) to -$276.39M. Figures come from the company's audited annual reports as filed with the SEC.